The FDA approves remibrutinib for symptomatic dermographism, the first such therapy, extending an oral BTK inhibitor label via the Phase III RemIND trial.
|Articles|May 23, 2013
Keofitt sampling bags
The main products for this category is the unique single-use sampling bag systems allowing safe and aseptic sampling from any type of sterilizable sampling valve.
Advertisement
Keofitt sampling bags
The Keofitt Sampling Bags have all been developed as single-use solutions to the cumbersome and difficult task of taking a representative sample and bringing it safe and clean from the sampling point to the laboratory.
At the same time the Keofitt Sampling Bags offer convenience and safety in use and higher efficiency in the work process. No prior assembly or cleaning of any components; no glass or metal component is introduced to the production area.
All Keofitt Sampling Bags are made of medical grade plastics complying with all relevant FDA, USP and ISO regulations for both the food and the pharmaceutical/biotech industries.
The Keofitt Sampling Bags are delivered separately packed and sterilized by irradiation. In each carton a Radiation Certificate and a Certificate of Conformity are enclosed.
The Keofitt Sampling Bags are manufactured following strict in-process testing including a test for endotoxins.
The proper performance of all Keofitt Sampling Bags is supported by a number of validation documents covering SIP’ability, biocompatibility, extractables, USP Class VI, endotoxins, mechanical and chemical properties etc.
The product range comprises 4 types:
- STERILE Sampling Bags (single bag)
- ASEPTIC Sampling Bags (single bag with valve system for steaming)
- SPIKE Sampling Bags (single bag)
- Three60 Sampling Bag System (multiple bag closed system)
Contact details:
KEOFITT A/S
Website: link name
Advertisement
Related to this article
The company is showcasing new development solutions and advanced digital technologies including its new OSD Express and Steriles Express solutions for drug development.
Ron Scarboro, Azurity Pharmaceuticals, explains when formulation robustness justifies added cost and which post-approval quality and supply metrics teams can track.
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
Richard Jaenisch explains why NAMs are compressing drug development faster than AI and what FDA's new nonclinical testing rule means for sponsors.
Shadow AI and vendor data retention put GMP records and trade secrets at risk. AI Pulse Check panelists outline what pharma AI policies require.
Hovione's $35M CDC Flex line links spray drying to tablets, designed to eliminate scale-up under FDA Q13 guidance.
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
Advertisement
Advertisement